化合物AZA1 T61448
品牌 | 厂商性质 | 产地 | 货期 |
---|---|---|---|
TargetMol | 生产商 | 美国 | 现货 |
性能特点
生化试剂,可用于动物细胞实验
规格 | CAS号 | 价格 | 操作 |
---|---|---|---|
100 mg | 1071098-42-4 | ¥11,300.00 | 询底价 |
500 mg | 1071098-42-4 | ¥22,800.00 | 询底价 |
25 mg | 1071098-42-4 | ¥6,190.00 | 询底价 |
10 mg | 1071098-42-4 | ¥3,850.00 | 询底价 |
5 mg | 1071098-42-4 | ¥2,390.00 | 询底价 |
50 mg | 1071098-42-4 | ¥8,490.00 | 询底价 |
1 mg | 1071098-42-4 | ¥995.00 | 询底价 |
1 mL | 1071098-42-4 | ¥2,630.00 | 询底价 |
Product Introduction
Bioactivity
英文名: AZA1
描述: AZA1 (Rac1/Cdc42-IN-1) 是一种有效的Rac1和Cdc42双重抑制剂。AZA1 诱导前列腺癌细胞凋亡,抑制癌细胞增殖,迁移和侵袭。
体外活性: AZA1 (Rac1/Cdc42-IN-1) (2-10 μM; 72 hours) impedes the proliferation of human 22Rv1 prostate cancer cells.[1]AZA1 (2-10 μM; 24 hours) diminishes phosphorylation of PAK1, AKT, and BAD in EGF-stimulated 22Rv1 prostate cancer cells.[1]AZA1 (10 μM; 24 hours) obstructs Rac1 and Cdc42-dependent cell cycle progression in 22Rv1 prostate cancer cells. AZA1 inhibits Rac1 and Cdc42-dependent migration of 22Rv1, DU 145, and PC-3 prostate cancer cells.[1]AZA1 influences cell motility and actin reorganization in prostate cancer cells by suppressing Rac1 and Cdc42 function through PAK1/2 phosphorylation.[1]
体内活性: AZA1 (Rac1/Cdc42-IN-1) (100 μg; i.p.; daily for 2 weeks) is potent in suppressing human 22Rv1 xenograft growth in mice (5 week-old athymic nu/nu (nude)) and improving survival. The suppressive effect of AZA1 on tumor growth was significant.[1]
存储条件: Powder: -20°C for 3 years | In solvent: -80°C for 1 year
溶解度: DMSO : 45.0 mg/mL (122.1 mM)
关键字: AZA1 | AZA 1 | AZA-1
相关产品: Perifosine | CCT 137690 | Tubastatin A | Omaveloxolone | HA15 | MC2590 | Ibandronate sodium monohydrate | PFK-158 | TAS6417 | Xanthoangelol
相关库: Anti-Cancer Compound Library | Bioactive Compounds Library Max | Kinase Inhibitor Library | Inhibitor Library | Cytoskeletal Signaling Pathway Compound Library | Anti-Cancer Active Compound Library | Bioactive Compound Library
化合物AZA1 T61448信息由TargetMol中国为您提供,如您想了解更多关于化合物AZA1 T61448报价、型号、参数等信息,欢迎来电或留言咨询。
注:该产品未在中华人民共和国食品药品监督管理部门申请医疗器械注册和备案,不可用于临床诊断或治疗等相关用途